Literature DB >> 21490399

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.

Aubrey C Chan1, Stavros G Drakos, Oscar E Ruiz, Alexandra C H Smith, Christopher C Gibson, Jing Ling, Samuel F Passi, Amber N Stratman, Anastasia Sacharidou, M Patricia Revelo, Allie H Grossmann, Nikolaos A Diakos, George E Davis, Mark M Metzstein, Kevin J Whitehead, Dean Y Li.   

Abstract

Cerebral cavernous malformations (CCMs) are a common type of vascular malformation in the brain that are a major cause of hemorrhagic stroke. This condition has been independently linked to 3 separate genes: Krev1 interaction trapped (KRIT1), Cerebral cavernous malformation 2 (CCM2), and Programmed cell death 10 (PDCD10). Despite the commonality in disease pathology caused by mutations in these 3 genes, we found that the loss of Pdcd10 results in significantly different developmental, cell biological, and signaling phenotypes from those seen in the absence of Ccm2 and Krit1. PDCD10 bound to germinal center kinase III (GCKIII) family members, a subset of serine-threonine kinases, and facilitated lumen formation by endothelial cells both in vivo and in vitro. These findings suggest that CCM may be a common tissue manifestation of distinct mechanistic pathways. Nevertheless, loss of heterozygosity (LOH) for either Pdcd10 or Ccm2 resulted in CCMs in mice. The murine phenotype induced by loss of either protein reproduced all of the key clinical features observed in human patients with CCM, as determined by direct comparison with genotype-specific human surgical specimens. These results suggest that CCM may be more effectively treated by directing therapies based on the underlying genetic mutation rather than treating the condition as a single clinical entity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490399      PMCID: PMC3083782          DOI: 10.1172/JCI44393

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation.

Authors:  J Zhang; R E Clatterbuck; D Rigamonti; D D Chang; H C Dietz
Journal:  Hum Mol Genet       Date:  2001-12-01       Impact factor: 6.150

2.  Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock.

Authors:  Mark T Uhlik; Amy N Abell; Nancy L Johnson; Weiyong Sun; Bruce D Cuevas; Katherine E Lobel-Rice; Eric A Horne; Mark L Dell'Acqua; Gary L Johnson
Journal:  Nat Cell Biol       Date:  2003-11-23       Impact factor: 28.824

Review 3.  [131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies].

Authors:  P Otten; G P Pizzolato; B Rilliet; J Berney
Journal:  Neurochirurgie       Date:  1989       Impact factor: 1.553

4.  Cerebral cavernous malformations. Incidence and familial occurrence.

Authors:  D Rigamonti; M N Hadley; B P Drayer; P C Johnson; K Hoenig-Rigamonti; J T Knight; R F Spetzler
Journal:  N Engl J Med       Date:  1988-08-11       Impact factor: 91.245

5.  Long-term results after stereotactic radiosurgery for patients with cavernous malformations.

Authors:  Toshinori Hasegawa; James McInerney; Douglas Kondziolka; John Y K Lee; John C Flickinger; L Dade Lunsford
Journal:  Neurosurgery       Date:  2002-06       Impact factor: 4.654

6.  A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.

Authors:  David A McDonald; Robert Shenkar; Changbin Shi; Rebecca A Stockton; Amy L Akers; Melanie H Kucherlapati; Raju Kucherlapati; James Brainer; Mark H Ginsberg; Issam A Awad; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2010-10-11       Impact factor: 6.150

Review 7.  Branching morphogenesis of the Drosophila tracheal system.

Authors:  Amin Ghabrial; Stefan Luschnig; Mark M Metzstein; Mark A Krasnow
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

8.  Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations.

Authors:  Kevin J Whitehead; Nicholas W Plummer; Jennifer A Adams; Douglas A Marchuk; Dean Y Li
Journal:  Development       Date:  2004-03       Impact factor: 6.868

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31.

Authors:  Amy C Groth; Matthew Fish; Roel Nusse; Michele P Calos
Journal:  Genetics       Date:  2004-04       Impact factor: 4.562

View more
  64 in total

Review 1.  Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices.

Authors:  Anastasia Sacharidou; Amber N Stratman; George E Davis
Journal:  Cells Tissues Organs       Date:  2011-10-13       Impact factor: 2.481

Review 2.  Apicobasal polarity of brain endothelial cells.

Authors:  Thomas Worzfeld; Markus Schwaninger
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-06       Impact factor: 6.200

Review 3.  The pathobiology of vascular malformations: insights from human and model organism genetics.

Authors:  Sarah E Wetzel-Strong; Matthew R Detter; Douglas A Marchuk
Journal:  J Pathol       Date:  2016-12-04       Impact factor: 7.996

Review 4.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

Review 5.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

Review 6.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

7.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

8.  Cerebral Cavernous Malformations Develop Through Clonal Expansion of Mutant Endothelial Cells.

Authors:  Matthew R Detter; Daniel A Snellings; Douglas A Marchuk
Journal:  Circ Res       Date:  2018-10-26       Impact factor: 17.367

Review 9.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Lack of CCM1 induces hypersprouting and impairs response to flow.

Authors:  Tara M Mleynek; Aubrey C Chan; Michael Redd; Christopher C Gibson; Chadwick T Davis; Dallas S Shi; Tiehua Chen; Kandis L Carter; Jing Ling; Raquel Blanco; Holger Gerhardt; Kevin Whitehead; Dean Y Li
Journal:  Hum Mol Genet       Date:  2014-07-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.